Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rak piersi potwierdzony badaniem histologicznym, bez nadekspresji białka HER2
- •Dla raka HER2+ z receptorami estrogenowymi: wcześniejsze leczenie inhibitorem CDK4/6 i hormonoterapią
- •Dla potrójnie ujemnego raka piersi: brak wymaganych wcześniejszych leków przeciwnowotworowych
- •Przerzuty do mózgu potwierdzone obrazowaniem
- •Możliwość wykonania rezonansu magnetycznego (MRI)
- •Dostępne zmienione tkanki spoza mózgu, które można pobrać do biopsji
- •Chęć poddania się biopsji guza i zdolność podpisania zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 15, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Rochester
Rochester, United States
Trial contact
Jamie Littleton
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.